Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

28.6%

2 terminated/withdrawn out of 7 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
4(80.0%)
Phase 2
1(20.0%)
5Total
N/A(4)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT04100291Not ApplicableTerminated

Faecal Microbiota Transplantation in the Treatment of Chronic Pouchitis

Role: lead

NCT04820413Not ApplicableCompleted

Faecal Microbiota Transplantation From Normal Pouch Function Donor in the Treatment of Chronic Pouchitis

Role: lead

NCT04835402Phase 2Unknown

Electroporation Potentiated Immunotherapy in Cancer

Role: lead

NCT04093141Not ApplicableUnknown

Chemotherapy Followed by Irreversible Electroporation in Patients With Unresectable Locally Advanced Pancreatic Cancer

Role: lead

NCT04404647Not ApplicableWithdrawn

Irreversible Electroporation of Unresectable Liver Tumors

Role: lead

NCT02480790Unknown

Venous Thromboembolic Complications in Ovarian Cancer

Role: lead

NCT02928120Unknown

Diagnostic Potential of Hypermethylated DNA in Colorectal Cancer

Role: lead

All 7 trials loaded